KAPE-TECHNOLOGIES
1.8.2024 14:12:36 CEST | Business Wire | Press release
Kape Technologies today announced the appointment of Ankit Khemka as Chief Marketing Officer (CMO), strengthening the group’s senior leadership team and bolstering the company’s commitment to building a safer, freer internet with its industry-leading privacy and security technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801380656/en/
Ankit Khemka (Photo: Business Wire)
Khemka is a seasoned professional with a diverse background in Brand Building, Growth Marketing and strategic business development. Most recently, Khemka served as Global General Manager and Head of Marketing at Revolut. Prior to this, he worked at HelloFresh and Rocket Internet Group, building and scaling businesses across the US, India, Europe, and Latin America.
Khemka will leverage his global experience in fast-growing companies to accelerate the growth of Kape’s privacy products, including its flagship privacy brand, ExpressVPN. In his new position, he will lead marketing activities, reinforcing the company’s strong customer-centric culture and driving initiatives to maximize growth opportunities.
"I am delighted to appoint Ankit to propel the next chapter of growth and innovation for Kape Technologies and its brands. The leadership team and I share a strong vision for the future of Kape. I am confident that Ankit’s marketing leadership and vision will be invaluable to our team as we continue to grow and innovate,” said Charles Butler, CEO, Kape Technologies. “Together we remain laser-focused on our mission to establish Kape as the world’s leading privacy-first digital security provider, empowering customers to take control of their privacy and security.”
Ankit Khemka, CMO, Kape Technologies said, “Kape Technologies’ flagship brand, ExpressVPN, has been at the forefront of the VPN industry for over a decade, thanks to its dedication to technical excellence, innovation, and customer-centricity. I am excited to build upon this solid foundation and unlock the immense potential for further growth. With our shared vision and the combined strength of our team, I am confident that we will take the company to new heights, setting the standard for the privacy and security industry.”
About Kape Technologies
Kape Technologies is a leading privacy-first digital security software provider to consumers. Through its range of privacy and security products, Kape focuses on protecting consumers and their personal data as they go about their daily digital lives.
With over 7 million paying subscribers, Kape has a proven track record of growth, underpinned by a strong business model and expert digital marketing. Kape's highly scalable SaaS-based operating structure is geared toward capitalizing on the vast global consumer digital privacy market.
About ExpressVPN
Since 2009, ExpressVPN has empowered millions of users to take control of their internet experience. The company’s award-winning consumer VPN service is backed by its open-source VPN protocol Lightway, delivering user privacy in just a few clicks. ExpressVPN’s Keys password manager and Aircove router make digital privacy and security easy and accessible for all. ExpressVPN’s products have been extensively vetted by third-party experts, including PwC, Cure53, KPMG, and others.
ExpressVPN has been part of Kape Technologies since 2021. To learn more about ExpressVPN’s industry-leading privacy and security solutions, visit www.expressvpn.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801380656/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
